HeartSciences toont MyoVista® Wavelet ECG tijdens European Society of Cardiology Congress (ESC) 2018
SOUTHLAKE, Texas–(BUSINESS WIRE)–
HeartSciences, een medische hulpmiddelenbedrijf dat ECG-apparaten van de volgende generatie ontwikkelt met behulp van CWT-signaalverwerking (continuous wavelet transform) en kunstmatige intelligentie, is trots om zijn deelname als exposant aan te kondigen op het komende European Society of Cardiology Congress (ESC) in 2018. Het congres vindt plaats in Messe München International in München, Duitsland en is van 25 tot en met 29 augustus. Heartsciences zal daar de MyoVista® Wavelet ECG (wavECG™) voor hartproeven onder de aandacht brengen, evenals de recente klinische onderzoeksresultaten, gepubliceerd in het Journal of the American College of Cardiology (JACC).
Dit persbericht bevat multimedia. Bekijk de volledige weergave hier: https://www.businesswire.com/news/home/20180820005047/en/
Het JACC artikel met de titel “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presenteert de resultaten van de door onderzoekers geïnitieerde klinische studie die zich richtte op het evalueren van de haalbaarheid van MyoVista® Wavelet ECG als diagnostisch hulpmiddel voor het voorspellen van hartspierontspanningsafwijkingen. De resultaten van het onderzoek laten zien dat MyoVista’s gepatenteerde technologie op basis van CWT-signaalverwerking hartspierontspanningsafwijkingen kan detecteren die geassocieerd worden met LVDD.
HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)
SOUTHLAKE, Texas–(BUSINESS WIRE)–
Hall A, Booth G320
HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence, is proud to announce its participation as an exhibitor at the upcoming 2018 European Society of Cardiology Congress (ESC). The Congress will take place at Messe Munich International in Munich, Germany and will run from August 25 to August 29, 2018. HeartSciences will highlight its MyoVista® Wavelet ECG (wavECG™) Cardiac Testing Device as well as recent clinical study results published in the Journal of the American College of Cardiology (JACC)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180820005047/en/
The JACC article titled “Prediction of Abnormal Myocardial Relaxation from Signal Processed Surface ECG” presented the results from the investigator-initiated clinical study that focused on evaluating the feasibility of MyoVista® Wavelet ECG as a diagnostic tool for predicting myocardial relaxation abnormalities. Results from the study demonstrate MyoVista’s patented technology based on CWT signal processing can detect myocardial relaxation abnormalities associated with LVDD.
About HeartSciences
HeartSciences is advancing the field of electrocardiography through the application of wavelet signal processing and artificial intelligence to develop next generation ECG technology. Wavelet signal processing is currently used in many different industries as an important tool to provide insights and new valuable data related to spectral analysis of a signal. HeartSciences’ MyoVista wavECG Cardiac Testing Device is a 12-lead resting electrocardiograph utilizing continuous wavelet transform (CWT) based signal processing. Patented informatics focus on energy related information rather than conventional voltage-based information. HeartSciences mission is to enable accurate, affordable screening for the early detection of heart disease.
In addition to the proprietary informatics, the MyoVista wavECG Device also features the capabilities of a full featured 12-lead resting ECG including analysis using the Glasgow Algorithm, one of the world’s most respected interpretive algorithms. The device has a 15.6-inch high-resolution touchscreen display and incorporates many features commonly associated with a tablet device requiring minimal user training as well as easy and intuitive use. The MyoVista wavECG Device is not currently approved for sale or distribution in the United States and is not currently FDA cleared.
HeartSciences is a privately-held U.S. corporation based in Southlake, Texas.
For more information visit www.heartsciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180820005047/en/
Contacts
HeartSciences
Gene Gephart, +1-737-346-1089
gene.gephart@heartsciences.com< br/>or
Investor Contact
Zimmons International Communications
Jennifer K. Zimmons, +1-917-214-3514
jzimmons@zimmonsic.com